58267-85-9Relevant academic research and scientific papers
Organic small molecular semiconductor material containing anthracene dithiophene as well as preparation method and application thereof
-
Paragraph 0032; 0033; 0034, (2018/06/16)
The invention discloses an organic small molecular semiconductor material containing anthracene dithiophene as well as a preparation method and an application thereof. The structural formula of the material is as shown in a formula I, wherein the unit A is an electron deficient group; R1 is hydrogen or alkyl with 1-30 carbon atoms or a group in the alkyl with 1-30 carbon atoms, one or more of which are replaced by halogen atoms, oxygen atoms, alkenyl, alkynyl, aryl, hydroxyl, amino, carboxyl, ester groups, cyan or nitryl. The material has unique advantages of relatively good light capturing ability, proper electronic energy level, relatively high electronic mobility and the like, and is applied to organic solar battery apparatuses as an electron acceptor material to obtain good apparatus performances.
Enantioselective Rhodium-Catalyzed Dimerization of ω-Allenyl Carboxylic Acids: Straightforward Synthesis of C2-Symmetric Macrodiolides
Steib, Philip,Breit, Bernhard
supporting information, p. 6572 - 6576 (2018/05/08)
Herein, we report on the first enantioselective and atom-efficient catalytic one-step dimerization method to selectively transform ω-allenyl carboxylic acids into C2-symmetric 14- to 28-membered bismacrolactones (macrodiolides). This convenient asymmetric access serves as an attractive route towards multiple naturally occuring homodimeric macrocyclic scaffolds and demonstrates excellent efficiency to construct the complex, symmetric core structures. By utilizing a rhodium catalyst with a modified chiral cyclopentylidene-diop ligand, the desired diolides were obtained in good to high yields, high diastereoselectivity, and excellent enantioselectivity.
Four and ring kinase inhibitors
-
Paragraph 0220; 0221; 0222; 0223, (2017/07/01)
The invention belongs to the technical field of medicines and relates to a tetra-cyclo-kinase inhibitor shown in the general formula (I) and its pharmaceutically acceptable salt, stereisomer, ester or solvate. In the general formula (I), R1, R2, R3, R4, M, W, X, Y and Z are defined in the specification. The invention also relates to a preparation method of the compounds, a drug containing the compounds, and a use of the compounds and its pharmaceutically acceptable salt, stereisomer, ester or solvate in preparation of a drug for treating and/or preventing ALK-mediated cancer-related diseases.
Four and circular Anaplastic lymphoma kinase inhibitors
-
Paragraph 0248-0250, (2017/08/02)
The invention belongs to the technical field of medicine, and more specifically relates to a tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor represented by general formula (I), and pharmaceutically acceptable salts, stereisomers, esters, or solvates thereof, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, R7, M, X, and Y are defined by the patent specification. The invention also relates to preparation methods of the compounds above, pharmaceutic preparations and pharmaceutical compositions containing the compounds, and applications of the tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor, the pharmaceutically acceptable salts, the stereisomers, the esters, or the solvates in preparing medicines used for treating and/or preventing ALK mediated cancer related diseases.
Four and circular Anaplastic lymphoma kinase inhibitors
-
Paragraph 0378; 0380; 0381; 0382; 0383, (2017/08/25)
The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.
NOVEL FUSED HETEROCYCLES AND USES THEREOF
-
Page/Page column 47, (2010/02/14)
This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.
Substituted heteroarylalkanoic acids
-
, (2008/06/13)
Disclosed are substituted heteroarylalkanoic acids acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.
CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS
-
Page/Page column 57, (2010/02/07)
The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions which are related to irregular calcification.
Fused pyridine derivatives
-
Example 161, (2010/01/30)
The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.
